

IMPLEMENTATION AND MONITORING OF A PROTOCOL FOR THE USE OF **INTRAVENOUS IRON**

López Suárez, Diego; Álvarez Martín, Tamara; Cuesta López, Isabel; Castañeda Macías, Isabel; Fernández García, María Elisa


BACKGROUND

The Pharmacy and Therapeutics Committee approved in May 2017 a protocol for the prescription of intravenous iron in order to achieve a correct use of it in the hospital, and establishing iron sucrose complex as first choice in admitted patients.


ΟΑ

PURPOSE

 \checkmark The objective of this study was to assess the degree of adaptation of the prescriptions to the protocol.



Main reasons for prescription




RΤ	Patient's body weight
DA	Iron metabolism data (transferrin saturation, serum ferritin and iron)
E	Pharmaceutical product prescribed (ferric carboxymaltose or sucrose)
D	

Review if administered doses were correct taking into account the theoretical deficiency calculated according to Ganzoni formula

Dose was considered correct if the difference between the administered dose and the theoretical deficiency was not exceeding ±500 mg in ferric carboxymaltose and **±200 mg in sucrose**

Ferric carboxymaltose was the pharmaceutical product chosen in most of patients





The total dose administered did not match the theoretical deficiency calculated in 41.3% of cases.



- ✓ The lack of data in many orders received in the Pharmacy Department makes it difficult to verify the appropriateness of the prescription to the protocol in many cases. Therefore highlights the protocolization is a dynamic process that requires a continuous assessment to ensure its utility.
- ✓ Ferric carboxymaltose was used more frequently in the iron replenishment in outpatients and iron sucrose in hospitalized patients.

